Evidence map›Paper›PMID 42367808›Full record

ArticleFrontiers in immunology2026

Mygalin reduces inflammation by targeting TLR3 signaling pathway in macrophages.

Nayara Del Santos, Ricardo Vázquez-Ramírez, Abraham Espinoza-Culupú, Elizabeth Mendes, Mayara de Oliveira Cavalcante, Pedro Ismael Silva Junior, Monamaris Marques Borges

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nayara Del SantosBacteriology Laboratory, Butantan Institute, São Paulo, Brazil.
Ricardo Vázquez-RamírezInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Abraham Espinoza-CulupúLaboratory of Molecular Microbiology and Biotechnology, Faculty of Biological Sciences, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Elizabeth MendesBacteriology Laboratory, Butantan Institute, São Paulo, Brazil.
Mayara de Oliveira CavalcanteBacteriology Laboratory, Butantan Institute, São Paulo, Brazil.
Pedro Ismael Silva JuniorLaboratory for Applied Toxinology (LETA), Butantan Institute, São Paulo, Brazil.
Monamaris Marques BorgesBacteriology Laboratory, Butantan Institute, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLRs) are central regulators of innate immunity, enabling macrophages to detect pathological changes through both cell surface and intracellular compartments. Several molecules have been investigated for their ability to modulate TLR-mediated immune responses. Mygalin, a synthetic acylpolyamine analogue of spermidine, has been reported to modulate macrophage activation via extracellular TLR2 and TLR4 pathways. Here, we investigated the immunomodulatory effects of Mygalin on RAW 264.7 macrophages activated with Poly I:C (TLR3 agonist), LPS (TLR4 agonist), and IFN-γ using

Indexed as

InflammationMacrophagesSignal TransductionToll-Like Receptor 3AnimalsMacrophage ActivationMiceMolecular Docking SimulationMolecular Dynamics SimulationRAW 264.7 CellsToll-Like Receptor AgonistsTLR3 protein, mouseToll-Like Receptor 3Toll-Like Receptor Agonistscell signalinginflammationinnate immunitymolecular dockingmolecular dynamicsMygalinRAW 264.7 macrophagesTLR3

Identifiers

PMID42367808
PMCPMC13303013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.